Photocure ASA has completed the acquisition of Vesica Health for approximately USD 30.5 million in cash and stock, expanding its bladder cancer diagnostic portfolio. Vesica Health's AssureMDx is a urine-based molecular test that improves early detection and risk stratification of bladder cancer, addressing a large market of hematuria patients in the U.S. The test has strong clinical validation and regulatory recognition, including FDA Breakthrough Device status and potential Medicare reimbursement. Photocure aims to accelerate AssureMDx commercialization using its established infrastructure, expecting initial revenues in 2027 and positive EBITDA by 2030, enhancing growth and profitability in bladder cancer diagnostics.
Bitcoin miners are experiencing declining revenue as the network's hash rate and mining difficulty fall, reflecting a shift of miners into AI infrastructure. Despite this stress, miners are accumulating Bitcoin, with reserves increasing by 1%, signal...
Lululemon invested in Syntetica's $30 million Series A funding to support its innovative recycling of Nylon 6 and Nylon 6,6, materials difficult to separate and reuse in textile waste. This move aligns with growing industry demand for sustainable, co...
Ethereum futures long positions among top traders increased by over 3 percentage points across both USDT- and coin-margined markets, indicating a broad-based shift in short-term sentiment. This rise suggests heightened attention on ETH compared to ot...
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
